Skip to main content

Committee Leaders Continue to Probe How 340B Program Savings are Used to Help Patients


Letter Builds on Recent #SubOversight Document Request and Hearing

WASHINGTON, DC – Energy and Commerce Committee Chairman Greg Walden (R-OR) and Oversight and Investigations Subcommittee Chairman Tim Murphy (R-PA) today sent a series of letters to a diverse group of covered entities participating in the 340B Drug Pricing Program.

Following the committee’s June 2017 request for information from HHS’ Health Services and Resources Administration (HRSA), and #SubOversight’s July 2017 hearing, the letters will broaden the committee’s understanding of how program savings are calculated and used by covered entities to help patients.

Citing testimony from the committee’s recent hearing, Walden and Murphy wrote, “…HRSA does not know whether 340B entities pass program savings on to patients who need a reduction in the price of their medicine because the statute is silent and hospitals are not required under the law to pass the savings on to patients.”

The committee leaders also wrote, “…[A] 2014 study by the Office of Inspector General at the U.S. Department of Health and Human Services found that not all covered entities ensure that uninsured patients benefit from the discounted 340B prices at their contract pharmacies.”

Click HERE to read the letters.